Adaptimmune Therapeutics plc (473A F) stock market data APIs
€0.2304
0(0%)
as of July 18, 2025
Try our APIs with
free plan!
Adaptimmune Therapeutics plc Financial Data Overview
Price chart is built with
Anychart
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Prev. Close
0.2304
Open
0.2304
High
0.2304
Low
0.2304
52 wk Range
0.142-1.25
Market Cap
60 962 K
Shares Outstanding
265 M
Revenue
180 M
EPS
-0.1064
Beta
2.255
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adaptimmune Therapeutics plc data using free add-ons & libraries
Get Adaptimmune Therapeutics plc Fundamental Data
Adaptimmune Therapeutics plc Fundamental data includes:
- Net Revenue: 180 M
- EBITDA: -36 358 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-08-09
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adaptimmune Therapeutics plc News
New
Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC
On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned investment management firm, expanded its investment portfolio by adding a significant number of shares in Adaptimmune Therapeutics ...
Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
This month, we saw the Adaptimmune Therapeutics plc (NASDAQ:ADAP) up an impressive 58%. But only the myopic could ignore the astounding decline over three years. Indeed, the share price is down a whop...
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune Therapeutics ADAP is a clinical-stage biopharmaceutical company focused on developing novel T-cell therapies targeting cancer indications. The most advanced candidate in the company’s p...
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; project...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
